Stoke Breakthrough Status for Treatment of Dravet Syndrome

 – Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over available therapies –

– Update on the company’s plans for a global, randomized, controlled Phase 3 registrational study anticipated by year-end –

https://www.businesswire.com/news/home/20241204329451/en/